Global Health Limited
Financial trend (95/100) does the heavy lifting; valuation (7/100) is the drag.
ExpensiveOvervaluedGlobal Health Limited earns a Hold from StocksWizard, with a blended score of 45/100. On 63.7x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,432.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,420.82 implies about 1% upside across 17 analysts. It clears 9 of 13 investability checks, with durability 69, valuation 14 and momentum 88 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹636.84.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-1.91% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 15.0%
- Pass: Low debt (D/E < 0.5): 0.30x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 25%
- Pass: Earnings growing: 42%
- Pass: Net margin ≥ 10%: 12.6%
- Pass: Current ratio > 1.5: 2.67
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 12.56
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter67.0%
- Institutions23.1%
- Public & other9.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 12.56.
Opportunities
- Earnings growing (42% YoY).
- Revenue growing (25% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~43% above our estimated fair value.
About Global Health Limited
Global Health Limited operates healthcare facilities in India offering specialized medical services across multiple disciplines. Its treatment areas include digestive and hepatobiliary sciences, cardiac care, cancer care, neurosciences, gastrosciences, orthopaedics, renal care, organ transplants (liver, lung, and bone marrow), chest surgery, gynecology and gyneoncology, pediatric care, obstetrics, emergency medicine, ENT, head and neck surgery, internal medicine, and respiratory and sleep medicine.
Global Health Limited — frequently asked questions
Is Global Health Limited a buy, hold or sell?
StocksWizard currently rates Global Health Limited (MEDANTA) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Global Health Limited's fair value?
Our blended DCF and relative-valuation model estimates Global Health Limited's fair value at about ₹796.05, versus a current price of ₹1,405.6 — roughly 43% downside. On that basis the stock looks overvalued by 43%.
Is Global Health Limited financially healthy?
Global Health Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Global Health Limited's share price performed?
Global Health Limited is up 20% over three months, and last traded at ₹1,405.6. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.